Dario Neri, Ph.D
Chief Executive Officer & Chief Scientific Officer
Co-founder
Dario Neri is Co-founder, CEO, CSO and President of the Scientific Advisory Board of Philogen. He graduated in Chemistry at the Scuola Normale Superiore in Pisa and obtained his Ph.D. in Chemistry from ETH Zurich, under the supervision of Prof. Kurt Wüthrich, winner of the Nobel Prize for Chemistry in 2002. For his dissertation, he was awarded the Silver Medal of ETH. After a 5 years post-doctoral research position in the lab of 2018 Chemistry Nobel Price Winner Sir Gregory Winter at the Cambridge Centre of Protein Engineering in Cambridge, UK, he returned to ETH Zurich in 1996 as Assistant Professor in Molecular Structure Biology. From 1999 he has been a Professor of Biomacromolecules in the Department of Chemistry and Applied Biosciences at ETH Zurich. He permanently joined Philogen in 2020, while retaining the Professor title of ETH Zürich. He is also a Honorary Senior Visiting Fellow of the University of Cambridge.
Prof. Neri is recipient of numerous awards, including the ISOBM Abbott Prize 2000, of the Amgen-Dompe’ Biotec Award 2000, the Prous Award 2006 of the European Federation of Medicinal Chemistry, of the Phoenix Prize 2014, of the Paul Harris Award 2022, and of the Pratesi Medal of the Italian Chemical Society 2023. He is author of more than 500 publications in international scientific journals.
Duccio Neri
Executive Chairman
Co-founder
Duccio Neri is Co-founder and Chairman of Philogen. He graduated in Business Administration and Economics at the Bocconi University in Milan, specializing in Corporate Finance. Dr. Neri has a special expertise in Financial Consulting, Tax and Audit Advice and Business Administration and is a Partner of the “Studio Neri – Tanini”. He was a representative of the Italian Government in the Board of the University of Siena and an auditor of the Cassa di Risparmio di San Miniato (CRSM) S.p.A., MPS Banca Verde S.p.A., MPS Fiduciaria S.p.A., MPS Professional S.p.A., and of several other firms.
Giovanni Neri, Ph.D.
Head of Licensing & IP
Co-founder
Giovanni Neri is Co-founder and Director of IP & Licensing at Philogen S.p.A. Dr. Neri graduated in Biology at the University of Siena where he also received his doctorate in Biotechnology. He later specialized in antibody therapeutics in clinical oncology at the Royal Postgraduate Medical School at the Hammersmith Hospital, London from 1993 to 1995. At Philogen, he is responsible for developing the company’s patent portfolio and is involved in the conclusion of all the major contractual agreements.
Sergio Dompé
Sergio Dompé
In 1976 Sergio Dompé joins Dompé farmaceutici S.p.A. – a family company founded in 1940 by his father and expands the business. Among the first in Italy to grasp the true value of biotechnology applied to human health, he has developed an extensive network of partnerships with the most significant research centers for diseases in Dompé’s main therapeutic fields, whose global network amounts now to 300 centers. In 2020 he promoted and coordinated the public-private consortium Exscalate4CoV supported by the European Commission’s Horizon 2020 programme to fight the Covid-19 pandemic. At the same time, in 2020, through the Dompé Foundation, he has launched a program of international scholarships open to students of all nationalities for advanced training in the field of Life Sciences, with particular attention to translational approaches. He is currently Executive President and CEO of Dompé Holdings S.r.l., Dompé farmaceutici S.p.A., Movendo Technology S.r.l. and member of the Board of Asset Italia S.p.A. and of Il Sole 24 Ore. The Dompé Group currently counts on the contribution of more than 900 people and a 2024 turnover of 1234 millions €uro. From 1998 to 2004 Sergio Dompé was President of Assobiotec; from 2005 to 2011 President of Farmindustria; from 2007 to 2015 member of the Board of the IIT (Italian Institute of Technology) Foundation; from 2014 to 2016 member of the Board of Regency of the Bank of Italy (Milan office) and from 2016 to 2022 Censor of the Bank of Italy (Milan office); Since 2015 member of the General Council of Confindustria; from 2019 until 2025 Vice President of Assolombarda with delegated powers over Life Sciences; since 2020 Chairman of the 2021 B20 Life Sciences task-force; since 2023 President of Comitato Leonardo – Italian Quality Committee. In 2004 Sergio Dompé was awarded the “La Lombardia per il lavoro” prize, in recognition of his value as one of Lombardy’s most innovative entrepreneurs. In 2016, he received the Prize of the Foundation Aiuto per la Ricerca sulle Malattie Rare (A.R.M.R.), regularly awarded to those who distinguish themselves in the research field. In 2017 he was awarded the Guido Carli prize. As an entrepreneur in the pharmaceutical and biotechnology sectors, he has been awarded honorary doctorates in Biotechnology with specialization in pharmaceutics (Bologna, 1996), Medical Biotechnology (L’Aquila, 2005) and Pharmacy (Urbino, 2010).
Nathalie Dompé
Nathalie Dompé is the Co-CEO of Dompé Farmaceutici S.p.A., where she leads strategic innovation and market development. She is specifically focused on fostering strong partnerships with leaders in the pharmaceutical and technology sectors to help build Dompé into what the modern pharmaceutical company looks like in the age of AI and advanced applied biology. In addition to her leadership role, Nathalie is also the CEO of Dompé Holdings S.r.l., her family’s holding company, and serves on the board of directors of several technology businesses, including Movendo Technology S.r.l. Nathalie graduated in Business Administration from Bocconi University in Milan and lives in Silicon Valley with her husband and children.
Marta Bavasso
Independent Director
Marta Bavasso is partner of Scanzano-Pesce-Bavasso Studio Legale where she advises on corporate and commercial law with particular focus in M&A and private equity, fund structuring, joint ventures, and commercial contracts.
She is a graduate of the University of Florence and has studied international and EU law at University College London. She has practiced at several leading law firms including MacKenzie Mills (currently Withers LLP), Ernst & Young and Chiomenti, as well as in-house at Enel S.p.A. and Group Hutchinson Whampoa Limited, for the launch of H3G Italy (now Wind Tre).
She has also served as independent director on the boards of First4Progress S.p.A. (group First Capital S.p.A.) and Ericsson Telecomunicazioni S.p.A, and is currently independent director at Generalfinance S.p.A. (GF – BIT) and B&C Speakers (BEC_BIT)
In addition to her native Italian, she is fluent in English and French.
She is a member of AISCA, Associazione Italiana Segretari del Consiglio di Amministrazione e per la Corporate Governance and NedCommunity.
Patrizia Sacchi
Chiara Falciani
Chiara Falciani is an Associate Professor of Biochemistry at the Department of Medical Biotechnology, University of Siena, Italy. She holds a Ph.D. in Chemical Sciences and a Master’s Degree in Pharmaceutical Chemistry and Technology from the University of Florence, and completed training at the University of Göttingen, Germany.
She holds the Italian National Scientific Qualification for Full Professor in both Clinical Biochemistry and General Biochemistry, and in April 2025 she was selected as the winner of a public competition for a Full Professorship in Biochemistry at the University of Siena.
Her career includes roles as tenure-track assistant professor and research fellow in biochemistry. She also worked in the biotech sector as founder and R&D director of Setlance Srl and as a scientific consultant for private companies. She teaches Chemistry and Biochemistry at the School of Medicine and plays an active role in university governance, chairing the Joint Faculty-Student Committee and serving on multiple Rector-appointed task forces (Technology Transfer, International Education, Public Engagement, Placement). Her research focuses on biotechnological strategies for human health, particularly in oncology and infectious diseases. She has authored over 100 publications and presented extensively at national and international conferences, including invited and chair roles.
Flavia Scarpellini
Leopoldo Zambeletti
Mr. Zambeletti is an Independent Strategic and Financial Advisor in the Healthcare sector. During his 25-year career as an investment banker, Mr Zambeletti led the EMEA Healthcare Investment Banking team at JP Morgan for eight years before taking up the same position at Credit Suisse for a further five years. He is a Non-Executive Director of Nogra Pharma, Bactobio, Afimmune, Adler Ortho, Tema Sinergie, Touchlight Plc. And LenioBio Gmbh. Mr Zambeletti started his career at KPMG as an auditor and received a BA in Business from Bocconi University in Milan, Italy.